Charles F. Kettering

Memorial Sloan Kettering Cancer Center Launches MSKCC India to Expand Access to World-Renowned Oncologists, Cancer Care, Research, and Education

Retrieved on: 
Monday, August 2, 2021

NEW YORK andCHENNAI, India, Aug. 2, 2021 /PRNewswire/ --Memorial Sloan Kettering Cancer Center, the world's oldest and largest private cancer center,has launchedMSKCCIndia to provide cancer patients in India with access to the institution's world-renowned oncologists, research, clinical trials, and education.

Key Points: 
  • NEW YORK andCHENNAI, India, Aug. 2, 2021 /PRNewswire/ --Memorial Sloan Kettering Cancer Center, the world's oldest and largest private cancer center,has launchedMSKCCIndia to provide cancer patients in India with access to the institution's world-renowned oncologists, research, clinical trials, and education.
  • In some cases, they may recommend that the patient travel to receive care at Memorial Sloan Kettering Cancer Center in New York City.
  • "MSKCC India will help serve the needs of cancer patients and their physicians to improve their cancer care."
  • As part of this effort to bring world-class care to people in India diagnosed with cancer, Memorial Sloan Kettering Cancer Center has partneredwithiCliniq, a leadingglobaltelemedicine provider based inIndia.This partnership is the first of its kind for both iCliniq and Memorial Sloan Kettering Cancer Center.

Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neuroblastoma

Retrieved on: 
Wednesday, June 23, 2021

Based on our discussions with the FDA, we believe we now have a clearer path towards the resubmission of the omburtamab BLA to the FDA.

Key Points: 
  • Based on our discussions with the FDA, we believe we now have a clearer path towards the resubmission of the omburtamab BLA to the FDA.
  • Upon receiving the FDAs feedback on these items, we expect to move forward and request a Type B pre-BLA meeting.
  • Pending a positive Type B pre-BLA meeting, we aim to initiate rolling resubmission of the omburtamab BLA by the end of the year.
  • Researchers at Memorial Sloan Kettering Cancer Center (MSK) developed omburtamab, which is exclusively licensed by MSK to Y-mAbs.

BriaCell to Participate at Upcoming Conferences and Appoints Senior R&D Director

Retrieved on: 
Tuesday, May 11, 2021

Williams will also participate in a panel discussion titled \xe2\x80\x9cInvesting Post COVID \xe2\x80\x93 Back to the Fundamentals\xe2\x80\x9d at 11:50am ET on May 13, 2021.

Key Points: 
  • Williams will also participate in a panel discussion titled \xe2\x80\x9cInvesting Post COVID \xe2\x80\x93 Back to the Fundamentals\xe2\x80\x9d at 11:50am ET on May 13, 2021.
  • The panel will discuss healthcare investing in the post COVID world.\nInvestors may request one-on-one meetings with Dr. Williams.\nInvestors may register for the conference here: https://www.benzinga.com/events/small-cap/global/ .\nDr.
  • Since 2000, Dr. Lopez-Lago has been working as a cancer scientist at Memorial Sloan-Kettering Cancer Center, New York (MSKCC).
  • Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate.

Diaprost Announces Promising New Study for Patients with Metastatic PCa

Retrieved on: 
Monday, February 22, 2021

The extensive preclinical study was conducted at Memorial Sloan Kettering Cancer Center (MSK) on Diaprost's propriety antibody (hu5A10) targeting PSA.

Key Points: 
  • The extensive preclinical study was conducted at Memorial Sloan Kettering Cancer Center (MSK) on Diaprost's propriety antibody (hu5A10) targeting PSA.
  • "These results clearly show that PSA-targeted alpha-particle therapy is a very promising option for patients with generalized and castration resistant PCa" said Johan Drott, the CEO of Diaprost.
  • "There is an urgent need for therapeutic compounds that result in substantial treatment effects and long-term survival in patients with metastatic PCa.
  • MSK has intellectual property rights and associated interests related to Diaprost by virtue of the licensing agreement between MSK and Diaprost.

Diaprost Announces Promising New Study for Patients with Metastatic PCa

Retrieved on: 
Monday, February 22, 2021

The extensive preclinical study was conducted at Memorial Sloan Kettering Cancer Center (MSK) on Diaprost's propriety antibody (hu5A10) targeting PSA.

Key Points: 
  • The extensive preclinical study was conducted at Memorial Sloan Kettering Cancer Center (MSK) on Diaprost's propriety antibody (hu5A10) targeting PSA.
  • "These results clearly show that PSA-targeted alpha-particle therapy is a very promising option for patients with generalized and castration resistant PCa" said Johan Drott, the CEO of Diaprost.
  • "There is an urgent need for therapeutic compounds that result in substantial treatment effects and long-term survival in patients with metastatic PCa.
  • MSK has intellectual property rights and associated interests related to Diaprost by virtue of the licensing agreement between MSK and Diaprost.

Ken Pribil Jr. Foundation Supports Angiosarcoma Research at Memorial Sloan Kettering Cancer Center for a Third Year

Retrieved on: 
Monday, February 15, 2021

ROCKVILLE CENTRE, N.Y., Feb. 15, 2021 /PRNewswire-PRWeb/ --The Ken Pribil Jr. Foundation recently made its seventh annual Sarcoma Research Grant, in the amount of $10,000, to support angiosarcoma research being performed at Memorial Sloan Kettering Cancer Center (MSK) in New York, NY.

Key Points: 
  • ROCKVILLE CENTRE, N.Y., Feb. 15, 2021 /PRNewswire-PRWeb/ --The Ken Pribil Jr. Foundation recently made its seventh annual Sarcoma Research Grant, in the amount of $10,000, to support angiosarcoma research being performed at Memorial Sloan Kettering Cancer Center (MSK) in New York, NY.
  • With the addition of this 2020 Ken Pribil Jr. Sarcoma Research Grant, the Ken Pribil Jr. Foundation has supported sarcoma research with over $55,000 in grants to research facilities in the New York area.
  • "We are proud to continue our partnership with Dr. Cristina Antonescu and her research team at Memorial Sloan Kettering as they've continued to make research advancements to combat angiosarcoma and identify novel therapeutic targets," said Kevin Pribil, President of the Board of Directors of the Ken Pribil Jr. Foundation.
  • Since its inception in 2006, the Ken Pribil Jr. Foundation has given research grants to benefit sarcoma research at various institutions, including the Children's Hospital at Montefiore in the Bronx, NY.

Agenda for Targovax's Capital Markets Day 18 February 2021

Retrieved on: 
Thursday, February 11, 2021

OSLO, Norway, Feb. 11, 2021 /PRNewswire/ -- Targovax ASA, a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, will host a virtual Capital Markets Day for investors, analysts and journalists on 18 February 2021 at 2:30 PM CET.

Key Points: 
  • OSLO, Norway, Feb. 11, 2021 /PRNewswire/ -- Targovax ASA, a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, will host a virtual Capital Markets Day for investors, analysts and journalists on 18 February 2021 at 2:30 PM CET.
  • The Capital Markets Day will feature presentations from executive management and Alexander Shousthari, Medical Oncologist at Memorial Sloan Kettering Cancer Center, and will be webcast live and accessible at https://www.targovax.com/en/capital-markets-day-2021/
    Based on the strong clinical data that are now generated on ONCOS-102, Targovax has a solid fundament to move into late stage clinical development.
  • We also have a broader pipeline of preclinical assets that could create a broader horizon of opportunities in the future.
  • The Capital Markets day will feature presentations updating the market on these aspects.

Agenda for Targovax's Capital Markets Day 18 February 2021

Retrieved on: 
Thursday, February 11, 2021

OSLO, Norway, Feb. 11, 2021 /PRNewswire/ -- Targovax ASA, a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, will host a virtual Capital Markets Day for investors, analysts and journalists on 18 February 2021 at 2:30 PM CET.

Key Points: 
  • OSLO, Norway, Feb. 11, 2021 /PRNewswire/ -- Targovax ASA, a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, will host a virtual Capital Markets Day for investors, analysts and journalists on 18 February 2021 at 2:30 PM CET.
  • The Capital Markets Day will feature presentations from executive management and Alexander Shousthari, Medical Oncologist at Memorial Sloan Kettering Cancer Center, and will be webcast live and accessible at https://www.targovax.com/en/capital-markets-day-2021/
    Based on the strong clinical data that are now generated on ONCOS-102, Targovax has a solid fundament to move into late stage clinical development.
  • We also have a broader pipeline of preclinical assets that could create a broader horizon of opportunities in the future.
  • The Capital Markets day will feature presentations updating the market on these aspects.

Y-mAbs Announces Update on Omburtamab in DIPG

Retrieved on: 
Thursday, November 19, 2020

The omburtamab data was presented by Dr. Evan Bander from Weill Cornell Medicine.

Key Points: 
  • The omburtamab data was presented by Dr. Evan Bander from Weill Cornell Medicine.
  • In a poster presentation, Dr. Bander presented infusion related data from the ongoing Phase 1 study in DIPG.
  • The potential to retreat DIPG patients with multiple doses of omburtamab is truly exciting.
  • Researchers at Memorial Sloan Kettering Cancer Center (MSK) developed omburtamab, which is exclusively licensed by MSK to Y-mAbs.

Stop & Shop Stores Raise Nearly $2.5M for Annual Help Cure Childhood Cancer Campaign

Retrieved on: 
Tuesday, October 27, 2020

QUINCY, Mass., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Stop & Shop today announced that its annual Help Cure Childhood Cancer campaign raised nearly $2.5 million for pediatric cancer research and care at Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center (MSK).

Key Points: 
  • QUINCY, Mass., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Stop & Shop today announced that its annual Help Cure Childhood Cancer campaign raised nearly $2.5 million for pediatric cancer research and care at Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center (MSK).
  • Stop & Shops Help Cure Childhood Cancer campaign took place throughout the month of September at all 400+ Stop & Shop stores across the East Coast.
  • We would like to thank our customers once again for their generosity in raising funds to support pediatric cancer care and research, shares Stop & Shop President, Gordon Reid.
  • MSK Kids, Memorial Sloan Ketterings pediatric oncology program, is dedicated to all children, young adults, and families facing childhood cancer.